SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ichiki Y, Smith E, LeRoy EC, Trojanowska M. Different effects of basic fibroblast growth factor and transforming growth factor-β on the two platelet-derived growth factor receptors' expression in scleroderma and healthy human dermal fibroblasts. J Invest Dermatol 1995; 104: 1247.
  • 2
    Postlethwaite AE. Role of T cells and cytokines in effecting fibrosis. Int Rev Immunol 1995; 12: 24758.
  • 3
    Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor α, and interferon-γ levels in sera from patients with scleroderma. Arthritis Rheum 1992; 35: 6772.
  • 4
    Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997; 24: 32832.
  • 5
    Atamas SP, Yurovsky VV, Wise R, Wigley FM, Goter Robinson CJ, Henry P, et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999; 42: 116878.
  • 6
    Salmon-Her V, Serpier H, Nawrocki B, Gillery P, Clavel C, Kalis B, et al. Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures: potential role in fibrosis. Arch Dermatol 1996; 132: 8026.
  • 7
    Hebbar M, Gillot JM, Hachulla E, Lassalle P, Hatron PY, Devulder B, et al. Early expression of E-selectin, tumor necrosis factor α, and mast cell infiltration in the salivary glands of patients with systemic sclerosis. Arthritis Rheum 1996; 39: 11615.
  • 8
    Alecu M, Geleriu L, Coman G, Galatescu L. The interleukin-1, interleukin-2, interleukin-6 and tumour necrosis factor α serological levels in localised and systemic sclerosis. Rom J Intern Med 1998; 36: 2519.
  • 9
    Pandey JP, Takeuchi F. TNF-α and TNF-β gene polymorphisms in systemic sclerosis. Hum Immunol 1999; 60: 112830.
  • 10
    Takeuchi F, Nabeta H, Fussel M, Conrad K, Frank KH. Association of the TNFa13 microsatellite with systemic sclerosis in Japanese patients. Ann Rheum Dis 2000; 59: 2936.
  • 11
    Gruschwitz MS, Albrecht M, Vieth G, Haustein UF. In situ expression and serum levels of tumor necrosis factor-α receptors in patients with early stages of systemic sclerosis. J Rheumatol 1997; 24: 193643.
  • 12
    Heilig B, Fiehn C, Brockhaus M, Gallati H, Pezzutto A, Hunstein W. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease. J Clin Immunol 1993; 13: 3218.
  • 13
    Majewski S, Wojas-Pelc A, Malejczyk M, Szymanska E, Jablonska S. Serum levels of soluble TNF α receptor type I and the severity of systemic sclerosis. Acta Derm Venereol 1999; 79: 20710.
  • 14
    Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, et al. Animal model of sclerotic skin. I. Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999; 112: 45662.
  • 15
    Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993; 73: 45767.
  • 16
    Ohya T, Kaneko Y. Novel hyaluronidase from streptomyces. Biochim Biophys Acta 1970; 198: 6079.
  • 17
    Saito H, Yamagata T, Suzuki S. Enzymatic methods for the determination of small quantities of isomeric chondroitin sulfates. J Biol Chem 1968; 243: 153642.
  • 18
    Imaizumi Y, Sugita S, Yamamoto K, Imanishi D, Kohno T, Tomonaga M, et al. Human T cell leukemia virus type-I Tax activates human macrophage inflammatory protein-3α/CCL20 gene transcription via the NF-κB pathway. Int Immunol 2002; 14: 14755.
  • 19
    Kunugi S, Fukuda Y, Ishizaki M, Yamanaka N. Role of MMP-2 in alveolar epithelial cell repair after bleomycin administration in rabbits. Lab Invest 2001; 81: 130918.
  • 20
    Bakowska J, Adamson IY. Collagenase and gelatinase activities in bronchoalveolar lavage fluids during bleomycin-induced lung injury. J Pathol 1998; 185: 31923.
  • 21
    Taraboletti G, D'Ascenzo S, Borsotti P, Giavazzi R, Pavan A, Dolo V. Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol 2002; 160: 67380.
  • 22
    Mackay AR, Ballin M, Pelina MD, Farina AR, Nason AM, Hartzler JL, et al. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastasis 1992; 12: 16884.
  • 23
    Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum tumor necrosis factor-α levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 1997; 24: 6635.
  • 24
    Kantor TV, Friberg D, Medsger TA Jr, Buckingham RB, Whiteside TL. Cytokine production and serum levels in systemic sclerosis. Clin Immunol Immunopathol 1992; 65: 27885.
  • 25
    Heilig B, Wermann M, Gallati H, Brockhaus M, Berke B, Egen O, et al. Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis. Clin Investig 1992; 70: 227.
  • 26
    Robak T, Gladalska A, Stepien H. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw 1998; 9: 14554.
  • 27
    Yamamoto T, Takahashi Y, Takagawa S, Katayama I, Nishioka K. Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(v) mice. J Rheumatol 1999; 26: 262834.
  • 28
    Yamamoto T, Eckes B, Krieg T. Bleomycin increases steady-state levels of type I collagen, fibronectin and decorin mRNAs in human skin fibroblasts. Arch Dermatol Res 2000; 292: 55661.
  • 29
    Breen E, Shull S, Burne S, Absher M, Kelley J, Phan S, et al. Bleomycin regulation of transforming growth factor-β mRNA in rat lung fibroblasts. Am J Respir Cell Mol Biol 1992; 6: 14652.
  • 30
    Cutroneo KR. Human SP-1 but not human AP-1 binding to the TGF-β element in 5′ flanking region of the rat PROα1(I) collagen gene. Mol Biol Rep 2000; 27: 1914.
  • 31
    Westermarck J, Hakkinen L, Fiers W, Kahari VM. TNF-R55-specific form of human tumor necrosis factor-α induces collagenase gene expression by human skin fibroblasts. J Invest Dermatol 1995; 105: 197202.
  • 32
    Abraham DJ, Shiwen X, Black CM, Sa S, Xu Y, Leask A. Tumor necrosis factor α suppresses the induction of connective tissue growth factor by transforming growth factor-β in normal and scleroderma fibroblasts. J Biol Chem 2000; 275: 152205.
  • 33
    Bradham DM, Igarashi A, Potter RL, Grotendorst GR. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 1991; 114: 128594.
  • 34
    Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst GR. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 1996; 107: 40411.
  • 35
    Grotendorst GR. Connective tissue growth factor: a mediator of TGF-β action on fibroblasts. Cytokine Growth Factor Rev 1997; 8: 1719.
  • 36
    Yuan W, Varga J. Transforming growth factor-β repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J Biol Chem 2001; 276: 3850210.
  • 37
    Zhang Y, Feng XH, Derynck R. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-β-induced transcription. Nature 1998; 394: 90913.
  • 38
    Verrecchia F, Pessah M, Atfi A, Mauviel A. Tumor necrosis factor-α inhibits transforming growth factor-β/Smad signaling in human dermal fibroblasts via AP-1 activation. J Biol Chem 2000; 275: 3022631.
  • 39
    Fakhoury H, Hillarby MC, Weiss JB. Increased gelatinase activity in systemic sclerosis dermal fibroblast cultures with unaltered gelatinase A mRNA expression. J Dermatol Sci 2002; 29: 629.
  • 40
    Overall CM, Wrana JL, Sodek J. Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-β1 in human fibroblasts: comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J Biol Chem 1991; 266: 1406471.
  • 41
    Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 110510.
  • 42
    Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 11257.
  • 43
    Brennan FM, Browne KA, Green PA, Jaspar JM, Maini RN, Feldmann M. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-α (cA2) therapy. Br J Rheumatol 1997; 36: 64350.